Evidence map›Paper›PMID 30117120›Full record

ArticleDrug delivery and translational research2018

Curcumin-loaded self-nanomicellizing solid dispersion system: part II: in vivo safety and efficacy assessment against behavior deficit in Alzheimer disease.

Ankit Parikh, Krishna Kathawala, Jintao Li, Chi Chen, Zhengnan Shan, Xia Cao, Xin-Fu Zhou, Sanjay Garg

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Effectiveness of Novel Drug Delivery System using Curcumin in Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Ankit ParikhSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia.
Krishna KathawalaSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia.
Jintao LiSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia.
Chi ChenSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia.
Zhengnan ShanSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia.
Xia CaoCentral laboratory, Second Affiliated Hospital of Kunming Medical University, Kunming, 650101, Yunnan Province, China.
Xin-Fu ZhouSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia. Xin-Fu.Zhou@unisa.edu.au.
Sanjay GargSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, 5000, Australia. Sanjay.Garg@unisa.edu.au.
University of South Australia · AUKunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin (CUR), a natural polyphenolic compound, is considered as one of the most potential candidates against Alzheimer disease (AD) by targeting multiple pathologies such as amyloid-beta, tau phosphorylation, and oxidative stress. Poor physicochemical profile and oral bioavailability (BA) are the major contributors to its failure in clinical trials. Lack of success in numerous drug clinical trials for the treatment of AD urges the need of repositioning of CUR. To overcome its limitation and enhance oral BA, Novel CUR Formulation (NCF) was developed using self-nanomicellizing solid dispersion strategy which displayed 117-fold enhancement in oral BA of CUR. NCF was tested using SH-SY5Y695 APP human neuroblastoma cell line against the cytotoxicity induced by copper metal ion, H

Indexed as

Administration, OralAlzheimer DiseaseAmyloid beta-PeptidesAnimalsCell LineCognitive DysfunctionCopperCurcuminDisease Models, AnimalDrug CompoundingHumansHydrogen PeroxideMaleMiceMicellesMice, TransgenicAmyloid beta-Peptidesamyloid beta-protein (1-42)CopperCurcuminHydrogen PeroxideMicellesPeptide FragmentsAPPSwe/PS1deE9 miceCurcuminLearning and memorySafety assessmentSoluplus

Identifiers

PMID30117120
OpenAlexW2885077443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.